艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

休市中 12-20 15:59:58 EST

70.17

+0.73

+1.05%

盘后70.17

+0.000.00%

18:27 EST

最高71.13	最低68.97	成交量430.14万
今开70.00	昨收69.44	日振幅3.11%
总市值76.49亿	流通市值75.08亿	总股本1.09亿
成交额3.02亿	换手率4.02%	流通股本1.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":70.17,"timestamp":1734728398487,"preClose":69.44,"halted":0,"volume":4301383,"hourTrading":{"tag":"盘后","latestPrice":70.17,"preClose":70.17,"latestTime":"18:27 EST","volume":1028497,"amount":72169572.419,"timestamp":1734737273693},"delay":0,"floatShares":107000000,"shares":109000000,"eps":1.809026,"marketStatus":"休市中","marketStatusCode":7,"change":0.73,"latestTime":"12-20 15:59:58 EST","open":70,"high":71.13,"low":68.97,"amount":301921471.14876,"amplitude":0.031106,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.809026,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":766296000000,"adjPreClose":69.44,"adrRate":0,"dividendRate":0.042497,"preHourTrading":{"tag":"盘前","latestPrice":69.55,"preClose":69.44,"latestTime":"09:13 EST","volume":36,"amount":2505.41316,"timestamp":1734704002917},"postHourTrading":{"tag":"盘后","latestPrice":70.17,"preClose":70.17,"latestTime":"18:27 EST","volume":1028497,"amount":72169572.419,"timestamp":1734737273693},"volumeRatio":4.477722891044755,"impliedVol":0.2357,"impliedVolPercentile":0.6706},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2493232541","title":"制裁风险暂时解除后，药明生物与美国药企就ADC新药达成合作，总交易额超8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493232541","media":"时代周报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493232541?lang=zh_cn&edition=full","pubTime":"2024-12-21 19:47","pubTimestamp":1734781667,"startTime":"0","endTime":"0","summary":"继美国2025年度国防授权法案未将《生物安全法案》纳入的消息传出后，药明生物（02269.HK）再度迎来好消息。12月20日，药明生物宣布和杭州多禧生物科技有限公司（下称“多禧生物”）与AadiBioscience（下称“Aadi”）达成研究服务合作协议，赋能Aadi公司研发三款处于临床前阶段的新一代抗体偶联药物（ADC，Antibody-drugconjugates）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412213275080854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1880383366.USD","LU0140636845.USD","LU0516422952.EUR","LU0516423091.SGD","LU0326950275.SGD","LU1242518931.SGD","02269","LU2039709279.SGD","LU0052750758.USD","SG9999002463.SGD","BK4231","LU0819121731.USD","BK1589","LU0320764599.SGD","LU0359201612.USD","BK1610","LU0043850808.USD","LU0417516902.SGD","LU0979878070.USD","SG9999002562.SGD","LU0307460666.USD","LU0588546209.SGD","BK4080","BK1521","LU0051755006.USD","LU0708995583.HKD","LU0823426308.USD","ADC","LU0348825331.USD","LU0417516738.SGD","LU0039217434.USD","LU0456846285.SGD","LU0516423174.USD","LU1242518857.USD","LU0823426480.USD","LU0359202008.SGD","LU0181495838.USD","LU0348735423.USD","IE00B0JY6N72.USD","LU0516422440.USD","LU0456827905.SGD","LU1794554557.SGD","LU0572944931.SGD","LU0327786744.USD","LU0856984785.SGD","LU1720050803.USD","LU0516422366.SGD","LU1688375341.USD","BK1141","BK1576"],"gpt_icon":0},{"id":"2493289870","title":"8.5亿美元 中国三条ADC管线出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2493289870","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493289870?lang=zh_cn&edition=full","pubTime":"2024-12-21 13:07","pubTimestamp":1734757625,"startTime":"0","endTime":"0","summary":"北京时间12月20日，药明生物（02269.HK）和杭州多禧生物共同宣布与AadiBioscience（AADI.US）达成研究服务合作协议。此次合作，Aadi将获得3项处于临床前阶段的抗体偶联药物（ADC）的开发、制造和商业化的全球独家许可权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412213275047554.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412213275047554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2492909794","title":"维立志博IPO：尚无商业化产品累亏超11亿 递表前一周政协委员突击入股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492909794","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492909794?lang=zh_cn&edition=full","pubTime":"2024-12-20 18:19","pubTimestamp":1734689940,"startTime":"0","endTime":"0","summary":"　　近日，南京维立志博生物科技股份有限公司进一步委任招银国际为IPO整体协调人。此前公司已于11月29日向港交所递表，摩根士丹利亚洲和中信里昂证券为其联席保荐人。　　维立志博于2012年成立，是一家临床阶段生物科技公司，致力于在肿瘤、自身免疫性疾病及其他重大疾病方面的创新疗法发现、开发及商业化。截至2024年6月30日，公司累计亏损额已达11.63亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-12-20/doc-ineachkr5780100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","BK1141","BK1583","BK1576","03347","BK4080","ADC"],"gpt_icon":0},{"id":"2492370654","title":"药明生物(02269)和多禧生物与Aadi Bioscience(AADI.US)就三款创新ADC达成研究服务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492370654","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492370654?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:21","pubTimestamp":1734657690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，全球领先的合同研究、开发和生产服务公司药明生物今日宣布和杭州多禧生物科技有限公司与Aadi Bioscience达成研究服务合作协议，赋能Aadi公司研发三款处于临床前阶段的新一代抗体偶联药物。Aadi Bioscience总裁兼首席执行官David Lennon博士指出，我们很高兴与药明生物和多禧生物达成合作，推进这些创新产品研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0052750758.USD","LU0516422366.SGD","LU0516423174.USD","BK4080","AADI","LU0039217434.USD","LU0051755006.USD","LU0979878070.USD","LU1880383366.USD","BK4139","LU0417516902.SGD","LU0516423091.SGD","LU0456846285.SGD","BK1610","BK1589","LU0823426308.USD","BK1521","LU0181495838.USD","LU1720050803.USD","02269","LU0588546209.SGD","LU0359202008.SGD","LU1688375341.USD","BK1576","SG9999002463.SGD","LU0326950275.SGD","LU0348735423.USD","LU0417516738.SGD","LU1794554557.SGD","LU0823426480.USD","LU0043850808.USD","LU0856984785.SGD","LU0516422952.EUR","LU0307460666.USD","BK1141","LU0327786744.USD","LU2039709279.SGD","ADC","LU0320764599.SGD","LU0708995583.HKD","BK4231","LU0140636845.USD","IE00B0JY6N72.USD","LU0516422440.USD","LU1242518857.USD","LU0359201612.USD","LU1242518931.SGD","SG9999002562.SGD","LU0348825331.USD","LU0572944931.SGD"],"gpt_icon":0},{"id":"2492112663","title":"港股异动 | 同源康医药-B(02410)涨超7%创新高 海外重磅ADC获突破性疗法认定 公司核心产品正进行临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112663","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492112663?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:03","pubTimestamp":1734591834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超7%创上市新高，盘中高见50.5港元，较招股价12.1港元已涨超300%。截至发稿，涨6.28%，报49.95港元，成交额1174.21万港元。海通证券指出，Dato-DXd获首个突破性疗法认定，为EGFR突变NSCLC患者带来新希望。招股书显示，同源康医药公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591、TY-302，5款创新临床产品，4款处于临床前阶段的产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1583","03347","BK4080","BK4231","02410","09939","BK1161","BK1515","BK1574","BK1576","BK1141","ADC"],"gpt_icon":0},{"id":"2492613731","title":"基石药业-B(02616)：CS5001(ROR1 ADC)全球多中心Ib期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492613731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492613731?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:08","pubTimestamp":1734566916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司管线2.0重磅产品CS5001全球多中心Ib期临床试验顺利完成首例患者入组。截至目前，CS5001在Ia期10个剂量组的剂量递增试验评估中，已展现出良好的安全性及明显的抗肿瘤活性。此外，在晚期实体瘤中，例如非小细胞肺癌、胰腺癌等，也观察到CS5001明显的疗效信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","ADC","BK1583","02616","BK4231","BK1141","BK1576","BK4080","BK1161","BK1574"],"gpt_icon":0},{"id":"2492587581","title":"Nuvation Bio Inc.盘中异动 下午盘快速下挫5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492587581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492587581?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:47","pubTimestamp":1734551224,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日03时47分，Nuvation Bio Inc.股票出现波动，股价快速跳水5.16%。截至发稿，该股报2.67美元/股，成交量119.681万股，换手率0.36%，振幅6.23%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为1.96%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219034705984cb742&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219034705984cb742&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4231","DDC","BK4080","BK4212","BK4007","NUVB","ADC"],"gpt_icon":0},{"id":"2492906326","title":"从上市到销售，ADC发展步入新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2492906326","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492906326?lang=zh_cn&edition=full","pubTime":"2024-12-18 18:22","pubTimestamp":1734517320,"startTime":"0","endTime":"0","summary":"获批分析基于Pharma-ONE中国上市药品数据库，截至2024.12.11，共有11个ADC产品获批。从2020年起，每年都至少有1个ADC获批上市，分布较为平均，同时2024年批准数量创新高，11月下旬至12月上旬捷报频传，短短两周时间内市场迎来3个新成员。图1 国内ADC产品每年获批数量统计医保分析基于Pharma-ONE医保目录数据库，已有5个ADC纳入了2024年国家医保目录，新增2个、续约3个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-18/doc-inczwuet7680540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2492920712","title":"港股异动 | 乐普生物-B(02157)再涨超11% MRG003有望25年下半年获批 TP ADC海外授权潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2492920712","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492920712?lang=zh_cn&edition=full","pubTime":"2024-12-18 14:57","pubTimestamp":1734505059,"startTime":"0","endTime":"0","summary":"乐普生物-B(02157)昨日放量涨超16%，今日午后再涨超11%，截至发稿，涨9.09%，报3.36港元，成交额6939.69万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20241218/20241218145750_64762.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241218/20241218145750_64762.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4080","BK1161","BK4231","02157","ADC"],"gpt_icon":0},{"id":"2492924420","title":"【港股通】翰森制药(03692)午后升近4% 新型ADC药物获临床试验批准及优先药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2492924420","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492924420?lang=zh_cn&edition=full","pubTime":"2024-12-18 13:47","pubTimestamp":1734500849,"startTime":"0","endTime":"0","summary":"金吾财讯 | 翰森制药(03692)临近午盘发力，午后升幅扩大，截至发稿，涨3.82%，报18.46港元，成交额6416.03万港元。公司日前公告，于2024年12月16日，集团自主研发的新型抗体–药物偶联物(ADC)注射用HS-20110获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展用于晚期实体瘤的临床试验。另外，公司近日公告，GSK就GSK5764227(GSK’227，亦称 HS-20093)获欧洲药品管理局(EMA)优先药物(PRIME)认定，此B7-H3靶向抗体药物偶联物(ADC)正在评估用于复发广泛期小细胞肺癌(ES-SCLC)患者的治疗。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK4231","ADC","HSTECH","BK1583","BK1191","BK1589","BK1141","BK4080","HSCEI","03347","03692","YANG"],"gpt_icon":0},{"id":"2492918256","title":"Nuvation Bio Inc.盘中异动 临近收盘股价大涨5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492918256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492918256?lang=zh_cn&edition=full","pubTime":"2024-12-18 04:54","pubTimestamp":1734468865,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日04时54分，Nuvation Bio Inc.股票出现异动，股价大幅上涨5.58%。截至发稿，该股报2.84美元/股，成交量126.092万股，换手率0.37%，振幅6.13%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.80%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121804542595ea36d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121804542595ea36d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","BK4007","NUVB","BK4080","BK4212","BK4231","ADC"],"gpt_icon":0},{"id":"2492984205","title":"港股异动 | 乐普生物-B(02157)盘中涨超18% ADC再现重磅出海交易 机构称TF ADC海外授权潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2492984205","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492984205?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:34","pubTimestamp":1734420878,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物-B盘中涨超18%，截至发稿，涨16.23%，报3.08港元，成交额1.17亿港元。国投证券此前指出，TF ADC早期数据优异，海外授权潜力大。乐普生物TF ADC已在ASCO 2024年会上披露了针对胰腺癌的优异数据，考虑到该领域严重的未满足临床需求，我们认为其海外授权潜力大。值得注意的是，乐普生物9月份公布，MRG003用于治疗复发性/转移性鼻咽癌新药上市申请获国家药监局受理并纳入优先审评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161","BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2491662362","title":"百奥赛图宣布Adcendo ApS行使抗体选择权以加速ADC开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2491662362","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491662362?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:00","pubTimestamp":1734343200,"startTime":"0","endTime":"0","summary":"Adcendo行使选择权，利用百奥赛图的全人抗体进一步扩展其ADC管线，开发针对高度未满足医疗需求的癌症的新型疗法。百奥赛图董事长兼CEO沈月雷博士表示：\"我们非常高兴能够通过百奥赛图先进的抗体发现平台，支持Adcendo在创新ADC药物领域的开发计划。结合Adcendo在ADC领域的丰富经验，我们相信此次合作将加速创新疗法的研发，造福全球患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4580315_ZH80315_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4231","BK4080","02315","BK1161","ADC"],"gpt_icon":0},{"id":"2491213463","title":"武大学霸创出一家IPO，泰格、贝达、金斯瑞押注","url":"https://stock-news.laohu8.com/highlight/detail?id=2491213463","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491213463?lang=zh_cn&edition=full","pubTime":"2024-12-13 20:18","pubTimestamp":1734092307,"startTime":"0","endTime":"0","summary":"尚无产品上市销售","market":"sg","thumbnail":"https://img2.gelonghui.com/ea749-949e2ece-77b6-470b-9590-28c6aee61dcc.png?guru_height=843&guru_width=1263","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/ea749-949e2ece-77b6-470b-9590-28c6aee61dcc.png?guru_height=843&guru_width=1263"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1478134","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2491406348","title":"中微半导推出高性价比触控 MCU-CMS79FT72xB系列","url":"https://stock-news.laohu8.com/highlight/detail?id=2491406348","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491406348?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:13","pubTimestamp":1734077609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4231","ADC","BK0214","PWM","688380","BK4080","BK4135"],"gpt_icon":0},{"id":"2490807055","title":"隐藏的头号ADC，不装了","url":"https://stock-news.laohu8.com/highlight/detail?id=2490807055","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490807055?lang=zh_cn&edition=full","pubTime":"2024-12-12 20:20","pubTimestamp":1734006000,"startTime":"0","endTime":"0","summary":"上方“瞪羚社”即刻关注并加入社群      聚焦高成长公司，100000+投资菁英共同关注      下一个中国ADC出海机会在哪？一个有10亿美金交易潜力的靶点——ROR1 ADC，藏不住了。  ....","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OrKVGFjc6QjzIKY_qK4DI7OVFlXy2iHKZsrXAq6b-pWfsAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OrKVGFjc6QjzIKY_qK4DI7OVFlXy2iHKZsrXAq6b-pWfsAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241212A094XR00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241212A094XR00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2490098892","title":"ASH数据出炉：隐藏的ADC王者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490098892","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490098892?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:58","pubTimestamp":1733824688,"startTime":"0","endTime":"0","summary":"在血液瘤领域，ADC的预期变得越来越明确。2023年销售额超过10亿美元的ADC中，辉瑞的Adcetris位居第二，罗氏的Polivy销售额也直逼10亿美元。复发是血液瘤难以逃脱的问题，而ADC与化疗、免疫治疗的机制并不相同，因此在血液瘤的后线治疗中仍能占据一席之地。另一方面，ADC还能成为前线疗法的有效手段。而在2024 ASH年会上，基石药业发布的CS5001最新临床数据，进一步引起了市场对于ROR1 ADC的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2463526074.USD","BK4080","ASH","BK4109","ADC","BK4231"],"gpt_icon":0},{"id":"2490592052","title":"阿斯利康(AZN.US)潜在重磅ADC获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490592052","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490592052?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:10","pubTimestamp":1733811019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共宣布，美国FDA授予其Trop2靶向抗体偶联药物datopotamab deruxtecan突破性疗法认定，用于治疗携带局部晚期或转移性表皮生长因子受体突变的非小细胞肺癌成人患者，这些患者在接受EGFR酪氨酸激酶抑制剂和铂类化疗后疾病仍出现进展。根据新闻稿，这是datopotamab deruxtecan首次获得突破性疗法认定。此次FDA授予突破性疗法认定主要是基于TROPION-Lung05临床2期试验数据，并加上TROPION-Lung01临床3期试验的支持性数据。18例患者中有10名(56%)出现脑部肿瘤直径总和缩小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4231","ADC","LU0889565916.HKD","BK4007","LU2417539215.USD","LU2462157665.USD","LU0320765992.SGD","LU2236285917.USD","LU1829250122.USD","BK4568","BK4080","AZN","LU0109394709.USD","LU2456880835.USD","BK4588"],"gpt_icon":0},{"id":"2490715370","title":"涨幅一度超过7%！基石药业CS5001（ROR1 ADC）展现同类最佳优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2490715370","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490715370?lang=zh_cn&edition=full","pubTime":"2024-12-09 14:13","pubTimestamp":1733724815,"startTime":"0","endTime":"0","summary":"重磅产品CS5001作为单药针对晚期淋巴瘤的最新临床数据，展现出良好的疗效和安全性","market":"hk","thumbnail":"https://img7.gelonghui.com/column/5.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1451065","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4231","BK1574","02616","BK4080","BK1161","ADC"],"gpt_icon":0},{"id":"2490798267","title":"港股异动 | 科伦博泰生物-B(06990)涨超5% ADC自研能力突出 多款产品即将进入商业化阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2490798267","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490798267?lang=zh_cn&edition=full","pubTime":"2024-12-09 10:18","pubTimestamp":1733710738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超5%，截至发稿，涨5.27%，报193.5港元，成交额5210.24万港元。天风证券发布研报称，科伦博泰拥有自主知识产权的ADC研发平台OptiDC，具备从研发到生产的全流程开发体系。截至2024年6月，公司共有5款ADC处于临床开发阶段，其中A166和SKB264 已经进入NDA阶段，SKB315 、SKB410和SKB518处于临床Ⅰ期阶段，多款产品处于临床前研究阶段。公司的ADC研发能力深受国际巨头默沙东认可，就SKB264以及其他在研品种达成多项合作，共计合作款项约118亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4231","BK4080","ADC","06990","LU0196878994.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0601},{"period":"1month","weight":-0.0888},{"period":"3month","weight":-0.0575},{"period":"6month","weight":0.141},{"period":"1year","weight":0.1242},{"period":"ytd","weight":0.1147}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":-0.004913},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.024183},{"month":8,"riseRate":0.451613,"avgChangeRate":0.001804},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005771},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.001244},{"month":11,"riseRate":0.645161,"avgChangeRate":0.002723},{"month":12,"riseRate":0.483871,"avgChangeRate":0.011511}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}